论文部分内容阅读
人工瓣膜置换术253例,术后早期病例49例。其中仅投予华法令22例(A组),授予华法令和潘生丁各300mg/日10例(B组),投予华法令和噻氯匹啶各300mg/日7例(C组)。投予华法令和噻氯匹啶各600mg/日10例(D组)。这些药物从术后第3日开始口服,调整各组华法令的用量使凝血酶原时间<30%。术后远期病例45例,其中口服华法令和潘生丁各300mg/日17例(Ⅰ组)。口服华法令和噻氯匹啶各300mg/日28例(Ⅱ组)。术后22日早期病例观察血小板数、血小板凝集力和血小板粘着性。术后远期病例每3个月检查血小板计数1次,共8次。自投药后Ⅰ组平均36.5个月,Ⅱ组27.6个月后,观察血小板凝集力、血小板粘着性各项指标。结果:术后早期和远期病例抗血小板药对血小板数量均无影响。血小板凝集抑制作用在投予抗血小板
253 cases of prosthetic valve replacement, 49 cases of early postoperative cases. Among them, only 22 cases were given warfarin (group A), 300 mg / day was given to each of warfarin and dipyridamole (group B), and 300 mg / day was given to warfarin and ticlopidine (group C). Warfarin and ticlopidine 600 mg / day were administered in 10 patients (group D). These drugs began orally on the third day after surgery and the amount of warfarin in each group was adjusted so that prothrombin time was <30%. Long-term postoperative patients 45 cases, of which oral warfarin and dipyridamole 300mg / day 17 cases (group Ⅰ). Warfarin and ticlopidine oral 300mg / day 28 cases (group Ⅱ). On the 22nd day after operation, the number of platelets, platelet cohesion and platelet adhesion were observed. Long-term postoperative patients every 3 months to check the platelet count 1, a total of 8 times. I group since the administration of an average of 36.5 months, Ⅱ group 27.6 months after the observation of platelet aggregation, platelet adhesion of the indicators. Results: The antiplatelet drugs had no effect on the number of platelets in early and long term postoperative patients. Platelet aggregation inhibition in the anti-platelet administration